keyword
MENU ▼
Read by QxMD icon Read
search

Non Clear Cell RCC

keyword
https://www.readbyqxmd.com/read/29133143/pathologic-and-clinical-characteristics-of-early-onset-renal-cell-carcinoma
#1
Tyler Clemmensen, Andres Matoso, Tiffany Graham, Win Shun Lai, Soroush Rais-Bahrami, Jennifer Gordetsky
The majority of RCCs occur within the 7th decade of life, uncommonly arising in adults ≤46years. We reviewed the clinicopathologic features of early-onset renal cell carcinoma (RCC) and evaluated the role of immunohistochemistry (IHC) in potentially identifying diagnoses of newly recognized RCC subtypes that may have been previously misclassified. A retrospective review was performed from 2011-2016 for cases of RCC. Early-onset RCC was defined as ≤46years of age. Clinicopathologic findings and hematoxylin and eosin (H&E) slides were reviewed on early-onset RCC patients...
November 10, 2017: Human Pathology
https://www.readbyqxmd.com/read/29056573/non-coding-rna-expression-and-targeted-next-generation-sequencing-distinguish-tubulocystic-renal-cell-carcinoma-tc-rcc-from-other-renal-neoplasms
#2
Charles H Lawrie, María Armesto, Marta Fernandez-Mercado, María Arestín, Lorea Manterola, Ibai Goicoechea, Erika Larrea, María M Caffarel, Angela M Araujo, Carla Sole, Maris Sperga, Isabel Alvarado-Cabrero, Michal Michal, Ondrej Hes, José I López
Tubulocystic renal cell carcinoma (TC-RCC) is a rare recently described renal neoplasm characterized by gross, microscopic and immunohistochemical differences from other renal tumor types that was recently classified as a distinct entity. However, this distinction remains controversial particularly as some genetic studies suggest a close relationship with papillary renal cell carcinoma (PRCC). The molecular basis of this disease remains largely unexplored. We therefore performed non-coding (nc)RNA/miRNA expression analysis and targeted next-generation sequencing mutational profiling on 13 TC-RCC cases (11 pure, two mixed TC-RCC/PRCC) and compared with other renal neoplasms...
October 19, 2017: Journal of Molecular Diagnostics: JMD
https://www.readbyqxmd.com/read/29050224/secreted-mir-210-3p-as-non-invasive-biomarker-in-clear-cell-renal-cell-carcinoma
#3
Vincenzo Petrozza, Antonio Luigi Pastore, Giovanni Palleschi, Claudia Tito, Natale Porta, Serena Ricci, Chiara Marigliano, Manuela Costantini, Giuseppe Simone, Angelina Di Carlo, Michele Gallucci, Antonio Carbone, Francesco Fazi
The most common subtype of renal cell carcinoma (RCC) is clear cell RCC (ccRCC). It accounts for 70-80% of all renal malignancies representing the third most common urological cancer after prostate and bladder cancer. The identification of non-invasive biomarkers for the diagnosis and responsiveness to therapy of ccRCC may represent a relevant step-forward in ccRCC management. The aim of this study is to evaluate whether specific miRNAs deregulated in ccRCC tissues present altered levels also in urine specimens...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29022072/effect-of-pathological-high-risk-features-on-cancer-specific-mortality-in-non-metastatic-clear-cell-renal-cell-carcinoma-a-tool-for-optimizing-patient-selection-for-adjuvant-therapy
#4
Marco Bandini, Ariane Smith, Emanuele Zaffuto, Raisa S Pompe, Michele Marchioni, Umberto Capitanio, Felix K Chun, Anil B Kapoor, Shahrokh F Shariat, Francesco Montorsi, Alberto Briganti, Pierre I Karakiewicz
PURPOSE: Adjuvant therapies for non-metastatic renal cell carcinoma (nmRCC) are being tested to improve outcomes in patients with high-risk (hR) nmRCC. The objective of the current study is to test the ability of three hR features to identify patients who are at the highest risk of cancer-specific mortality (CSM) after partial or radical nephrectomy. METHODS: Within the Surveillance Epidemiology and End Results (SEER) database (1988-2013), we identified 23,632 nm "clear cell" RCC partial or radical nephrectomy patients with hR features: Fuhrman grade (FG) 3 or 4 or pathological classifications T3a or T3b or lymph node invasion (LNI), or combination of these...
October 11, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/28986088/expression-of-tyrosine-kinase-receptor-axl-is-associated-with-worse-outcome-of-metastatic-renal-cell-carcinomas-treated-with-sunitinib
#5
Luís Eduardo Zucca, Mariana Andozia Morini Matushita, Renato José da Silva Oliveira, Cristovam Scapulatempo-Neto, Marcos Alves de Lima, Guilherme Gomes Ribeiro, Cristiano Ribeiro Viana, Flavio Mavignier Cárcano, Rui Manuel Reis
BACKGROUND: Renal cell carcinoma (RCC) represents 2%-3% of all cancers of the Western countries. Currently, sunitinib, a receptor tyrosine kinase inhibitor, particularly of PDGF and VEGF receptors, is the first-line therapy for metastatic RCC (mRCC), with significant improvement in clinical outcome. However, there is a lack of predictive biomarkers of sunitinib response. Recently, others and our group suggested that the receptor tyrosine kinase AXL may modify the response to sunitinib...
October 3, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28975890/identification-and-validation-of-novel-prognostic-markers-in-renal-cell-carcinoma
#6
Maj Rabjerg
Kidney cancer (Renal Cell Carcinoma (RCC)) is one of the most deadly malignancies due to frequent late diagnosis and poor treatment options. Histologically, RCC embraces a wide variety of different subtypes with the clear cell variant (ccRCC) being the most common, accounting for 75-90% of all RCCs. At present, the surveillance protocols for follow-up of RCC patients after radical nephrectomy are based on the American Joint Committee on Cancers (AJCC) pathological tumor-node-metastasis (TNM) classification system...
October 2017: Danish Medical Journal
https://www.readbyqxmd.com/read/28974261/the-150-most-important-questions-in-cancer-research-and-clinical-oncology-series-questions-57-66-edited-by-chinese-journal-of-cancer
#7
EDITORIAL
(no author information available yet)
Since the beginning of 2017, Chinese Journal of Cancer has published a series of important questions in cancer research and clinical oncology, which sparkle diverse thoughts, interesting communications, and potential collaborations among researchers all over the world. In this article, 10 more questions are presented as followed. Question 57. What are the major stresses that drive the formation, progression, and metastasis of a cancer? Question 58. What is the mechanism responsible for altering an acidic intracellular pH and a basic extracellular pH in normal tissue cells to a basic intracellular pH and an acidic extracellular pH in cancer cells, a fundamental and yet largely ignored phenomenon? Question 59...
October 3, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/28952411/clinical-development-of-mtor-inhibitors-for-renal-cancer
#8
REVIEW
Michele Ghidini, Fausto Petrelli, Antonio Ghidini, Gianluca Tomasello, Jens Claus Hahne, Rodolfo Passalacqua, Sandro Barni
Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney. In the last 10 years, clinical trials have established multitargeted tyrosine kinase inhibitors (TKIs) as the standard first-line treatment in patients with metastatic disease. Multiple agents are now available for treatment in subsequent lines.The mammalian target of rapamycin (mTOR) inhibitors (e.g., everolimus alone or with lenvatinib) are among the most effective options. Areas covered: This paper provides a complete and updated overview on mTOR inhibitors for the treatment of advanced RCC...
November 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28951115/characterization-and-impact-of-tert-promoter-region-mutations-on-clinical-outcome-in-renal-cell-carcinoma
#9
Jozefina Casuscelli, Maria F Becerra, Brandon J Manley, Emily C Zabor, Ed Reznik, Almedina Redzematovic, Maria E Arcila, Daniel M Tennenbaum, Mazyar Ghanaat, Mahyar Kashan, Christian G Stief, Maria Carlo, Martin H Voss, Darren R Feldman, Robert J Motzer, Yingbei Chen, Victor E Reuter, Jonathan A Coleman, Paul Russo, James J Hsieh, Abraham Ari Hakimi
BACKGROUND: Mutations in the promoter region of the TERT gene have been detected in a variety of cancers. These mutations can potentially lead to unlimited cell divisions and result in poor clinical prognosis. OBJECTIVE: To determine the role and relevance of TERT promoter region mutations in both clear cell (ccRCC) and non-clear cell (nccRCC) renal cell carcinoma using ultra-deep and whole-genome sequencing methods on primary tumor samples. DESIGN, SETTING, AND PARTICIPANTS: DNA from 281 kidney tumors (147 ccRCC and 134 nccRCC) was sequenced between 2013 and 2015, and clinical outcomes for these patients from a single institution were retrospectively analyzed...
September 23, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28936542/efficacy-of-percutaneous-radiofrequency-ablation-may-vary-with-clear-cell-renal-cell-cancer-histologic-subtype
#10
Timothy McClure, Allan Pantuck, James Sayer, Steven Raman
PURPOSE: The purpose of the study is to determine if clear cell renal cell cancer (RCC) subtype predicts efficacy in percutaneous radiofrequency (RF) ablation of RCC. METHODS AND MATERIALS: Patients who underwent percutaneous RF ablation for histologically proven RCC subtypes were retrospectively reviewed. Group comparisons were done using univariate and multivariate logistic regression analysis to determine factors impacting primary, secondary, and total technique effectiveness...
September 21, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28934212/outcome-of-papillary-versus-clear-cell-renal-cell-carcinoma-varies-significantly-in-non-metastatic-disease
#11
MULTICENTER STUDY
Nina Wagener, Dominic Edelmann, Axel Benner, Richard Zigeuner, Hendrik Borgmann, Ingmar Wolff, Laura M Krabbe, Mireia Musquera, Paolo Dell'Oglio, Umberto Capitanio, Tobias Klatte, Luca Cindolo, Matthias May, Sabine D Brookman-May
Renal cell carcinoma (RCC) comprises a heterogenous group of tumors. Traditionally, papillary RCC (pRCC) is associated with a favorable outcome compared to clear cell RCC (ccRCC), while other series report equivalent or worse prognosis. In this paper we comparatively evaluate outcome of pRCC versus ccRCC in two large multi-institutional databases (cohort study), including distribution of pRCC subtypes 1 and 2. Retrospective data of 1,943 surgically treated pRCC patients from 17 European/ North American centers between 1984-2015 were compared to 5,600 ccRCC patients from a database comprising 11 European/ North American centers (1984-2011)...
2017: PloS One
https://www.readbyqxmd.com/read/28928816/analysis-of-long-non-coding-rna-expression-profiles-in-clear-cell-renal-cell-carcinoma
#12
Fei Yan Yang, Yan Wang, Jian Guo Wu, Shao Li Song, Gang Huang, Wei Min Xi, Li Ling Tan, Jian Wang, Qing Cao
To investigate the expression patterns of long non-coding RNAs (lncRNAs) in clear cell renal cell carcinoma (ccRCC) and in metastatic renal cell carcinoma (RCC), the present study downloaded three human exon arrays available from the public Gene Expression Omnibus. The probes of the human exon arrays were re-annotated and the probes uniquely mapping to lncRNAs were retained at the gene level. Following the analysis of GSE53757 and GSE46699, which contained paired ccRCC cancer and normal adjacent tissue samples, 32 differentially expressed lncRNAs (adjusted P<0...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28913767/management-of-atypical-renal-cell-carcinomas
#13
REVIEW
Bobby C Liaw, Reza Mehrazin, Charles Baker, John P Sfakianos, Che-Kai Tsao
Non-clear cell renal cell carcinoma (RCC) encompasses a diverse group of diseases, with research yielding different histologic findings and genetic profiles with each distinct subgroup. Simply mirroring the management techniques of clear cell RCC and borrowing from its growing armamentarium of therapeutic agents, while somewhat productive at first, but will ultimately be limiting. Further investigation into the molecular pathogenesis of disease, similarities and differences between specific subtypes, and mechanisms of resistance to therapeutics will help identify new targets, stimulate development of novel agents, and improve clinical trial offerings for non-clear cell RCC (nccRCC)...
September 14, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28816276/-percutaneous-biopsy-of-the-renal-masses-under-ultrasound-a-single-center-14-years-experience
#14
Y X Zhang, X B Meng, L Yao, C J Zhang, G Song, L Cai, Z Zhang, X S Li, K Gong, S Q Li, G Z Shan, Q He, X Y Yang, Z S He, L Q Zhou
OBJECTIVE: To assess the diagnostic rate, safety and clinical application of percutaneous renal masses biopsy for advanced renal cell carcinoma patients. METHODS: In this retrospective study, we collected the data of renal masses from the patients who underwent renal masses biopsy under ultrasound from April 2001 to December 2014 in Peking University First Hospital. A total of 75 patients who were undiagnosed or diagnosed with advanced renal cell carcinoma by the imageological method were enrolled in this study...
August 18, 2017: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
https://www.readbyqxmd.com/read/28811845/role-of-contrast-enhancement-and-corrected-attenuation-values-of-renal-tumors-in-predicting-renal-cell-carcinoma-rcc-subtypes-protocol-for-a-triphasic-multi-slice-computed-tomography-ct-procedure
#15
Ersen Ertekin, Akın Soner Amasyalı, Bulent Erol, Saim Acikgozoglu, Faruk Kucukdurmaz, Alaaddin Nayman, Haluk Erol
BACKGROUND: To distinguish RCC subtypes based on contrast enhancement features of CT images. MATERIAL/METHODS: In total, 59 lesions from 57 patients were included. All patients underwent multi-slice CT imaging with a triphasic protocol, which included non-contrast, corticomedullary, nephrographic and urographic phases. Contrast enhancement features of renal masses were evaluated in terms of CT attenuation values (AV) and differences in contrast density; the aorta or renal parenchyma were evaluated based on corrected or relative values...
2017: Polish Journal of Radiology
https://www.readbyqxmd.com/read/28793269/cell-type-specific-gene-programs-of-the-normal-human-nephron-define-kidney-cancer-subtypes
#16
David Lindgren, Pontus Eriksson, Krzysztof Krawczyk, Helén Nilsson, Jennifer Hansson, Srinivas Veerla, Jonas Sjölund, Mattias Höglund, Martin E Johansson, Håkan Axelson
Comprehensive transcriptome studies of cancers often rely on corresponding normal tissue samples to serve as a transcriptional reference. In this study, we performed in-depth analyses of normal kidney tissue transcriptomes from the TCGA and demonstrate that the histological variability in cellularity, inherent in the kidney architecture, lead to considerable transcriptional differences between samples. This should be considered when comparing expression profiles of normal and cancerous kidney tissues. We exploited these differences to define renal-cell-specific gene signatures and used these as a framework to analyze renal cell carcinoma (RCC) ontogeny...
August 8, 2017: Cell Reports
https://www.readbyqxmd.com/read/28743221/components-of-metabolic-syndrome-and-prognosis-of-renal-cell-cancer
#17
Tommi J Eskelinen, Andres Kotsar, Teuvo L J Tammela, Teemu J Murtola
OBJECTIVE: This study analyzes risk associations between metabolic syndrome (MetS) components and the extent and prognosis of renal cell cancer (RCC). The independent effect of each MetS component is unclear, but they may affect RCC prognosis. MATERIALS AND METHODS: The study included 13,873 RCC patients (7720 men, 6153 women) diagnosed in Finland in 1995-2012. Data on MetS components (hypertension, dyslipidemia, diabetes and obesity) were obtained as recorded diagnoses or drug purchases related to these conditions...
July 26, 2017: Scandinavian Journal of Urology
https://www.readbyqxmd.com/read/28742884/reduced-expression-of-e-cadherin-and-increased-sialylation-level-in-clear-cell-renal-cell-carcinoma
#18
Małgorzata Borzym-Kluczyk, Iwona Radziejewska, Marzanna Cechowska-Pasko, Barbara Darewicz
Cancer cells are characterized by an aberrant increase in protein N-glycosylation and by disruption of E-cadherin-mediated adherens junctions. However, the relationship between alterations in N-glycosylation process and loss of E-cadherin adhesion in cancer remains unclear. The mechanisms of altered expression of adhesive glycoproteins in cancer cells have not been fully elucidated. Thus, the aim of this study was to examine the expression of E-cadherin and sialyl Lewis(a)/(x), NeuAcα2-3Gal, NeuAcα2-6Gal/GalNAc structures in the normal renal tissue and intermediate and cancerous tissues from patients with clear cell RCC...
2017: Acta Biochimica Polonica
https://www.readbyqxmd.com/read/28731496/prognostic-factors-for-survival-in-metastatic-renal-cell-carcinoma-patients-with-brain-metastases-receiving-targeted-therapy
#19
Ibrahim Yildiz, Ahmet Bilici, Nuri Karadurmuş, Leyla Ozer, Deniz Tural, Mehmet A Kaplan, Tülay Akman, Ibrahim V Bayoglu, Mükremin Uysal, Yaşar Yildiz, Özgür Tanriverdi, Ozan Yazici, Zeki Sürmeli, Nazim Serdar Turhal, Sevil Bavbek, Fatih Selçukbiricik, Doğan Koca, Mert Basaran
BACKGROUND: The primary objective of our study was to examine the clinical outcomes and prognosis of patients with metastatic renal cell carcinoma (mRCC) with brain metastases (BMs) receiving targeted therapy. PATIENTS AND METHODS: Fifty-eight patients from 16 oncology centers for whom complete clinical data were available were retrospectively reviewed. RESULTS: The median age was 57 years (range 30-80). Most patients underwent a nephrectomy (n = 41; 70...
July 14, 2017: Tumori
https://www.readbyqxmd.com/read/28728992/retroperitoneal-lymphadenectomy-in-high-risk-non-metastatic-renal-cell-carcinoma-an-analysis-of-the-assure-ecog-acrin-2805-adjuvant-trial
#20
Benjamin T Ristau, Judi Manola, Naomi B Haas, Daniel Y C Heng, Edward M Messing, Christopher G Wood, Christopher J Kane, Robert S DiPaola, Robert G Uzzo
PURPOSE: Lymphadenectomy (LND) is a well-established practice in many urologic malignancies; however, its role in renal cell carcinoma (RCC) is less clear. Our primary objective was to determine whether LND impacted survival in patients with fully resected high-risk RCC. PATIENTS AND METHODS: Patients with fully resected high-risk, non-metastatic RCC were randomized to adjuvant sorafenib, sunitinib, or placebo in the Adjuvant Sorafenib and Sunitinib for Unfavorable Renal Carcinoma (ASSURE) trial...
July 17, 2017: Journal of Urology
keyword
keyword
104989
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"